<DOC>
	<DOCNO>NCT01126437</DOCNO>
	<brief_summary>Direct comparison study tiotropium HandiHaler® 18 µg Respimat® 5 µg formulation limit 4-week crossover study . Therefore , prospective data trial adequate size duration require establish compare tiotropium HandiHaler® , tiotropium Respimat® ( ) similar effect safety ( b ) similar superior effect exacerbation .</brief_summary>
	<brief_title>Comparison Tiotropium HandiHaler Versus Respimat Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign informed consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline prior participation trial , include medication washout restriction . 2 . Male female patient 40 year age old . 3 . Patients must current exsmokers smoke history ≥10 packyears . ( Patients never smoke cigarette must exclude ) 4 . All patient must diagnosis COPD ( P0612085 ) , must meet following criterion : Relatively stable airway obstruction postbronchodilator FEV1 ≤ 70 % predict normal postbronchodilator FEV1 / FVC ≤70 % . Pulmonary function test ( PFTs ) conduct inhalation 400 μg salbutamol / albuterol ( prefer ) , however test either 200 μg salbutamol/albuterol combination salbutamol / albuterol ipratropium bromide ( 2 4 actuation ) acceptable . Other shortacting beta agonist , terbutaline , may use test . The medication use test document . Further , historical data measurement within past 6 month either site referral site may use ( see Section 6.2.1 CTP , locate Appendix 16.1.1 ) . Subjects randomize study without availability spirometry data actual study site . Eligibility PFT substudy : For subject participate spirometry substudy , historical data may use inclusion . These subject must qualify clinic Visit 1 perform baseline measurement . These subject perform predose PFT follow administration 400 μg salbutamol / albuterol ( shortacting beta agonist allow ) , follow postdose PFT qualification . 5 . Able inhale HandiHaler® Respimat® device . Exclusion criterion : 1 . Significant disease COPD . A significant disease define disease condition , opinion investigator , may put patient risk participation study may influence patient ability participate study . 2 . Patients recent history ( i.e. , six month less ) myocardial infarction . 3 . Patients unstable lifethreatening cardiac arrhythmia require intervention change drug therapy last year . 4 . Hospitalisation cardiac failure ( New York Heart Association ( NYHA ) Class III IV ) past year . 5 . Known active tuberculosis . 6 . Patients history asthma , cystic fibrosis , clinically evident bronchiectasis , interstitial lung disease , pulmonary thromboembolic disease . 7 . History thoracotomy pulmonary resection . Subjects history thoracotomy reason evaluate per exclusion criterion 1 . 8 . Subject plan undergo lung transplant lung volume reduction surgery ( LVRS ) . 9 . Malignancy subject undergone resection , radiation , chemotherapy biological treatment within last 5 year . Subjects treat basal cell carcinoma allow . 10 . Known respiratory infection exacerbation COPD 4 week prior randomization . 11 . Known hypersensitivity anticholinergic drug , lactose , benzalkonium chloride ( BAC ) , ethylenediaminetetraacetic acid ( EDTA ) , component HandiHaler® Respimat® inhalation solution delivery system . 12 . Known moderate severe renal impairment ( judged investigator ) . 13 . Known narrow angle glaucoma . 14 . Known significant symptomatic prostatic hyperplasia bladderneck obstruction . Subjects whose symptom control treatment may include . 15 . Use systemic corticosteroid medication unstable dos ( i.e. , less 6 week stable dose ) dose excess equivalent 10 mg prednisolone per day . 16 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception least 3 month prior duration trial . 17 . Significant alcohol drug abuse within past 12 month . 18 . Subjects require use supplemental oxygen therapy &gt; 12 hour per day . 19 . Subjects complete pulmonary rehabilitation program 6 week prior screen visit subject currently pulmonary rehabilitation program maintain throughout duration study . 20 . Subjects take investigational drug within 30 day prior Screening Visit . 21 . Previous participation ( receipt randomize treatment ) study . 22 . Subjects currently participate interventional study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>